Launch a product in a new market — or not yet, and not like this?

The question we answered, and the verdict

The client was weighing distribution of a well-known foreign consumer-supplement brand — several SKUs — into an EAEU / CIS market, with possible expansion. The question was not 'how to import' but 'is this viable, and in what configuration'. Our verdict — a conditional GO through gates: the project is viable, but only in a narrow configuration, and only if the pre-launch checks are passed in order, one by one. 'Better not to launch than launch and be wrong' plays out here not as refusal but as discipline: each critical risk is retired by its own check before any money is spent — not by betting on luck. The same Stage 0 also runs ahead of a decision to build your own production.

How we examined it (method)

The assessment runs in several stages, with an honesty check built into each one:

• A panel of domain specialists. The project was dissected by domain: the view 'from the counter', the evidence base behind claims, market and differentiation, sales channels, regulatory, law and advertising, tax, logistics/foreign trade, financial valuation, risk management.
• Adversarial verification. Every conclusion faced independent critique: an attack on each assumption and verification of each key figure and rule against primary legal sources.
• Iteration to convergence. The check caught internal contradictions and one material calculation error — we recomputed the model and reconciled the conclusions across blocks.

Three conclusions that decide everything else

Different experts, coming in from different angles, converged on three conclusions:

• No clinical exclusivity on any SKU. All the actives are generic. You cannot compete on a 'unique molecule' — only on format, price, channel and active recommendation. This is the direct answer to the 'single biggest question' of differentiation.
• The main economic lever is the channel, not the purchase price. Pharmacy chains take most of the margin through retro-bonuses, listing, shelf fees and payment delays: the distributor's net margin in pharmacy falls to 15–36%. Direct channels look different — marketplaces, an own online store, a practitioner's referral — they leave 53–72%. So it's better to start direct and bring the chains in as a second step, once there's real traction.
• Business value is a derivative of unproven sell-out. Until real sell-out (sale to the end consumer, not sell-in to the channel) is confirmed by a live pilot, the valuation is an option, not an asset.

Killer-risk discipline

A risk register with scoring (likelihood × impact) singles out the 'project-killers' — critical risks, each one closed by its own gate before any money is spent. The logic is simple: retire the risk with a cheap check first, then invest. Here are the risk types that come up most often:

• Regulatory reclassification. A heavily-dosed product risks failing to register as a supplement and slipping into the medicinal regime. The gate here is a registrability pre-screen on the real formulation, done before paying for any testing.
• No differentiation, so a price war. In saturated categories against entrenched brands, a price war eats the margin fast. The gate: don't push mass SKUs on a broad front — prove the lead product's format advantage first.
• Working-capital freeze. A large first order 'for the price', against unproven demand, plus the import-VAT cash gap at the border — it's a classic trap. The gate: start with a minimum batch, hold a liquidity reserve, and scale only once sales prove out.
• Advertising and claims law. A direct translation of foreign packaging text almost always drags in prohibited therapeutic claims. The gate is a legal read-through of everything — packaging and advertising — before products are listed and promotion starts.

The gated roadmap (before any purchase)

What comes next isn't 'buy and see' but a sequence of checks: each one retires its own risk before money is on the line.

1. 00

   Real price and terms

   Request the manufacturer's actual dealer price with minimum-order (MOQ) terms — replace the estimate with real figures and recompute the unit economics.

2. 01

   Registrability pre-screen

   Pre-screen the riskiest SKU against its real formulation — before paying for testing.

3. 02

   Shelf audit

   Walk the categories on the market (marketplaces + pharmacy chains) with a price audit — verify volumes and prices bottom-up, not from 'attractive' hypotheses.

4. 03

   Full registration dossier

   Assemble the dossier for the mandatory EAEU state registration (СГР) — a legalized manufacturer document package; run a legal read-through of claims.

5. 04

   Live direct-channel pilot

   Run 1–2 lead SKUs on a marketplace and through practitioners to measure real sell-out against a set break-even threshold.

6. 05

   A strong dealer contract

   Lock in market exclusivity, a sensible minimum batch with price tied to volume, and guarantees that registration documents will be provided.

Not investment advice. A sample of our Stage-0 market/niche research and feasibility work; the details come up in conversation.